首页 | 本学科首页   官方微博 | 高级检索  
     


Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors
Affiliation:1. Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA;2. Department of Radiation Oncology, Brigham and Women''s Hospital/Dana-Farber Cancer Institute, Boston, MA;3. Department of Computer Science and Statistics, University of Rhode Island, South Kingstown, RI;4. Department of Statistics, University of Connecticut, Storrs, CT;5. Department of Pathology, Baptist Hospital and Miami Cancer Institute, Miami, Florida;6. Mount Sinai School of Medicine, New York, NY;7. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
Abstract:BackgroundThe optimal use of new therapies in metastatic castration-resistant prostate cancer (mCRPC) remains to be clarified. Prostate-specific antigen (PSA) response used as a pharmacodynamic end-point may help identify patients with early resistance to new androgen receptor-pathway inhibitors. We aimed to determine the clinical significance of early PSA response (EPR) during therapy with enzalutamide, abiraterone acetate (AA) and orteronel in mCRPC.MethodsData from patients recruited in clinical trials were studied. PSA values were obtained at baseline and 28 d after treatment initiation. EPR defined as a decline >50% from baseline was calculated according to the Prostate Cancer Working Group 2 criteria. The effects of clinical characteristics on radiographic progression-free survival (rPFS) and overall survival (OS) were examined using the Cox model.ResultsEPR was assessed in 118 patients treated in clinical trials and was found to be associated with longer rPFS and OS (P < 0.0001 for both). Median rPFS was 13.9 and 5.6 months (hazard ratio [HR]:0.38, P < 0.001) for patients with and without an EPR, respectively. Median OS was 32.2 months in patients with an EPR and 15.9 months in patients without an EPR (HR: 0.4, P < 0.01). EPR remained prognostic for OS in multivariate analyses (HR: 0.5, p = 0.009) that included validated pre-therapeutic prognostic factors for mCRPC. Prognostic values of EPR for rPFS and OS were confirmed in an independent cohort of 95 AA-treated non-trial patients.ConclusionsEPR is an independent prognostic factor in patients with mCRPC treated with next-generation androgen pathway inhibitors and may be useful for the therapeutic management of these patients.
Keywords:Prostate cancer  PSA  Enzalutamide  Abiraterone
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号